Trial · NCT04833114
Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)
NCT04833114, Phase 3, Completed, GWT-TUD GmbH
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL). Trials, record NCT04833114. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04833114
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)
- NCT number
- NCT04833114
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 306 participants, actual
- Lead sponsor
- GWT-TUD GmbH
- Conditions
- Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
- Interventions
- Polatuzumab Vedotin, Mabthera, Ifosfamide, Carboplatin, Etoposide
- First posted
- 2021-04-06
- Last updated
- 2026-06-10
Source ClinicalTrials.gov
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Assessment of the event-free survival of patients with DLBCL at first progression and the occurrence of any of the following events: | Day of randomization until end of follow up (12 weeks treatment and at least 21 months follow up) | * Failure to achieve sufficient response in PET-CT (Deauville score 3 or less) at end of study treatment (metabolic CR) * Disease progression (PD) * Start of additional unplanned anti-tumor treatment (radiation therapy allowed) * Relapse after achieving CR * Death due to any cause |
| Secondary | Assessment of the rate of metabolic complete response. | Day of randomization until end weeks 12 treatment. | Number of complete remissions. |
| Secondary | Evaluation of the partial response rate. | Day of randomization until end of 12 weeks treatment. | Number of partial responses. |
| Secondary | Assessment of the overall response rate. | Day of randomization until end of 12 weeks treatment. | Number of complete and partial responses. |
| Secondary | Assessment duration of response. | Day of randomization until end of follow up (12 weeks treatment and at least 21 months follow up) | Time from documentation of tumor response to disease progression or relapse. |
| Secondary | Assessment of the rate of progressive disease. | Day of randomization until end of 12 weeks treatment. | Number of progressive diseases. |
| Secondary | Assessment of disease relapse. | Day of randomization until end of 12 weeks treatment. | Number of relapses. |
| Secondary | Assessment of progression free survival. | Day of randomization until end of follow up (12 weeks treatment and at least 21 months follow up) | Occurence of disease progression, relapse or death due to any cause. |
| Secondary | Assessment of overall survival. | Day of randomization until end of follow up (12 weeks treatment and at least 21 months follow up) | |
| Secondary | Assessment of the rate of patients proceeding to transplantation. | Day of randomization until week 12. |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04833114
GET https://conductscience.org/api/trials/v1/NCT04833114/registered